25C-NBOMe, a Novel Designer Psychedelic, Induces Neurotoxicity 50 Times More Potent Than Methamphetamine In Vitro
- PMID:30806983
- DOI: 10.1007/s12640-019-0012-x
25C-NBOMe, a Novel Designer Psychedelic, Induces Neurotoxicity 50 Times More Potent Than Methamphetamine In Vitro
Abstract
25C-NBOMe is a designer substituted phenethylamine and a high-potency psychedelic that acts on the 5-HT2A receptor. Although 25C-NBOMe overdoses have been related to several deaths in the USA and Europe, very limited data exists on the in vitro neurotoxicity of 25C-NBOMe. In this study, we found that 25C-NBOMe potently reduced cell viability of SH-SY5Y, PC12, and SN4741 cells, with IC50 values of 89, 78, and 62 μM, respectively. Methamphetamine decreased the cell viability of these cells with IC50 values at millimolar range in the same tests, indicating that 25C-NBOMe is > 50 times more potent than methamphetamine in its ability to reduce viability of SH-SY5Y cells. The neurotoxicity of 25C-NBOMe on SH-SY5Y cells was further confirmed by using fluorescein diacetate/propidium iodide double staining. 25C-NBOMe elevated the expression of phosphorylated extracellular signal-regulated kinase (pERK), but decreased the expression of phosphorylated Akt and phosphorylated Ser9- glycogen synthase kinase 3β (GSK3β) in time- and concentration-dependent manners. Interestingly, either specific GSK3β inhibitors or specific mitogen-activated protein kinase kinase (MEK) inhibitors significantly prevented 25C-NBOMe-induced neurotoxicity in SH-SY5Y cells. These results suggest that 25C-NBOMe unexpectedly produced more potent neurotoxicity than methamphetamine and that the inhibition of the Akt pathway and activation of the ERK cascade might be involved in 25C-NBOMe-induced neurotoxicity. Most importantly, these findings further inform the toxicity of 25C-NBOMe abuse to the central nervous system for public health.
Keywords: 25C-NBOMe; Designer drugs; ERK; GSK3β; Psychedelic; Substituted phenethylamine.
Similar articles
- 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe): clinical case with unique confirmatory testing.Stellpflug SJ, Kealey SE, Hegarty CB, Janis GC.Stellpflug SJ, et al.J Med Toxicol. 2014 Mar;10(1):45-50. doi: 10.1007/s13181-013-0314-y.J Med Toxicol. 2014.PMID:23872917Free PMC article.
- Death after 25C-NBOMe and 25H-NBOMe consumption.Morini L, Bernini M, Vezzoli S, Restori M, Moretti M, Crenna S, Papa P, Locatelli C, Osculati AMM, Vignali C, Groppi A.Morini L, et al.Forensic Sci Int. 2017 Oct;279:e1-e6. doi: 10.1016/j.forsciint.2017.08.028. Epub 2017 Sep 5.Forensic Sci Int. 2017.PMID:28893436
- The high frequency oscillation in orbitofrontal cortex is susceptible to phenethylamine psychedelic 25C-NBOMe in male rats.Yu ZP, Li Q, Wu ZX, Tang ZH, Zhang XQ, Wang ZC, Xu P, Shen HW.Yu ZP, et al.Neuropharmacology. 2023 Apr 1;227:109452. doi: 10.1016/j.neuropharm.2023.109452. Epub 2023 Jan 29.Neuropharmacology. 2023.PMID:36724866
- NBOMe: new potent hallucinogens--pharmacology, analytical methods, toxicities, fatalities: a review.Kyriakou C, Marinelli E, Frati P, Santurro A, Afxentiou M, Zaami S, Busardo FP.Kyriakou C, et al.Eur Rev Med Pharmacol Sci. 2015 Sep;19(17):3270-81.Eur Rev Med Pharmacol Sci. 2015.PMID:26400534Review.
- Toxicities associated with NBOMe ingestion-a novel class of potent hallucinogens: a review of the literature.Suzuki J, Dekker MA, Valenti ES, Arbelo Cruz FA, Correa AM, Poklis JL, Poklis A.Suzuki J, et al.Psychosomatics. 2015 Mar-Apr;56(2):129-39. doi: 10.1016/j.psym.2014.11.002. Epub 2014 Nov 6.Psychosomatics. 2015.PMID:25659919Free PMC article.Review.
Cited by
- Neuronal and peripheral damages induced by synthetic psychoactive substances: an update of recent findings from human and animal studies.Costa G, De Luca MA, Piras G, Marongiu J, Fattore L, Simola N.Costa G, et al.Neural Regen Res. 2020 May;15(5):802-816. doi: 10.4103/1673-5374.268895.Neural Regen Res. 2020.PMID:31719240Free PMC article.Review.
- Human Neuronal Cell Lines as An In Vitro Toxicological Tool for the Evaluation of Novel Psychoactive Substances.Sogos V, Caria P, Porcedda C, Mostallino R, Piras F, Miliano C, De Luca MA, Castelli MP.Sogos V, et al.Int J Mol Sci. 2021 Jun 24;22(13):6785. doi: 10.3390/ijms22136785.Int J Mol Sci. 2021.PMID:34202634Free PMC article.
- NBOMes-Highly Potent and Toxic Alternatives of LSD.Zawilska JB, Kacela M, Adamowicz P.Zawilska JB, et al.Front Neurosci. 2020 Feb 26;14:78. doi: 10.3389/fnins.2020.00078. eCollection 2020.Front Neurosci. 2020.PMID:32174803Free PMC article.Review.
- The use patterns of novel psychedelics: experiential fingerprints of substituted phenethylamines, tryptamines and lysergamides.Mallaroni P, Mason NL, Vinckenbosch FRJ, Ramaekers JG.Mallaroni P, et al.Psychopharmacology (Berl). 2022 Jun;239(6):1783-1796. doi: 10.1007/s00213-022-06142-4. Epub 2022 Apr 30.Psychopharmacology (Berl). 2022.PMID:35487983Free PMC article.
- Neurotoxic effects of hallucinogenic drugs 25H-NBOMe and 25H-NBOH in organotypic hippocampal cultures.Cassiano LMG, Oliveira MDS, de Barros WA, de Fátima Â, Coimbra RS.Cassiano LMG, et al.Heliyon. 2023 Jun 28;9(7):e17720. doi: 10.1016/j.heliyon.2023.e17720. eCollection 2023 Jul.Heliyon. 2023.PMID:37449113Free PMC article.
References
MeSH terms
Substances
Related information
Grants and funding
- 2017YFC0803605/the National Key Research and Development Program of China
- 81673407, 81870853, 81850410553/the National Natural Science Foundation of China
- 2017C50042/Ningbo Sci & Tech Project for Common Wealth
- 201804/Zhejiang Provincial Key Laboratory of Pathophysiology
- 2015C110026/Ningbo municipal innovation team of life science and health
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous